Background: Abnormal ␤-catenin immunohistochemistry and mutations of the ␤-catenin gene (CTNNB1) have been reported in adrenocortical adenomas (ACAs), but the frequencies of these defects and the phenotype of such tumors have not been clearly determined.
T
he ␤-catenin protein plays a central role in the Wnt signaling pathway. Specifically, ␤-catenin stimulates and/or maintains proliferation of adrenal cortical cells during embryonic development and is required for cell renewal in the adult adrenal cortex (1) . This protein plays a structural role in cell-cell adhesion and behaves like a transcriptional cofactor for the T cell factor/lymphoid enhancer factor (2, 3) . A Wnt/␤-catenin signaling pathway activation has been described in many tumor types, including colorectal, hepatocellular, and endometrial cancers (4 -10) . Studies of unilateral and bilateral adrenocortical tumors (ACTs) (3, (11) (12) (13) (14) suggest that constitutive activation of the Wnt/␤-catenin signaling pathway in adult adrenals is involved in the pathogenesis of both benign and malignant neoplasms (3, 11, 13, 14) . For example, in transgenic mice, constitutively active ␤-catenin has recently been shown to act as an adrenal oncogene able to induce adrenal hyperplasia and promote malignancy (15) . Genetic alterations of the Wnt/␤-catenin signaling pathway have been identified in humans and activating mutations in exon 3 of the somatic ␤-catenin gene (CTNNB1) are the most frequent defect in sporadic adrenocortical adenomas (ACAs) and adrenocortical carcinomas (ACCs) (3, 11, 13, 16) . However, because the published reports so far include only small cohorts, the exact frequency of the Wnt/␤-catenin signaling pathway activation is not clear nor is the associated ACT phenotype. Furthermore, the phenotype of ACA with activation of the Wnt/␤-catenin has also not been precisely described. However, it has been established that hepatocellular adenomas harboring CTNNB1 mutations are at greater risk of malignant transformation (17, 18) . In the present study, we assessed the Wnt/␤-catenin pathway alteration by ␤-catenin immunohistochemistry and together CTNNB1 mutations in a large series of 100 patients with resected ACAs (excluding Conn's adenoma). We aimed to determine the frequency of the Wnt/␤-catenin signaling pathway activation and its correlation with tumor phenotype.
Patients and Methods

Patients and tissue collection
From January 1988 to December 2007, 184 consecutive patients were operated for sporadic ACAs (other than Conn's adenoma and with Weiss score Յ2) in the Department of Digestive and Endocrine Surgery of Cochin Hospital and followed in the Endocrinology Department of Cochin Hospital. Overall, we were able to analyze frozen tumor fragments from 105 patients for mutations in CTNNB1. For each of these patients, we collected information concerning clinical data, hormonal status, tumor size, and weight on final pathological examination. Surgical nonsecreting adenomas (NSAs) were defined by the inability to exclude malignancy on the basis of imaging and normal hypothalamic-pituitary-adrenal (HPA) axis function. Subclinical cortisol secreting adenomas (SCSAs) were defined by the absence of Cushing's syndrome, normal 24-h urinary free cortisol (UFC), incomplete suppression to the 1-mg dexamethasone suppression testing (DST) (serum cortisol Ͼ50 nmol/liter), and at least one additional biological abnormality [low 8 h plasma ACTH (Ͻ2.2 pmol/liter)] or disruption of plasma cortisol circadian rhythm (0 h to 8 h serum cortisol ratio Ͼ0.5) as previously described (19) . Cortisol secreting adenomas (CSAs) were defined by clinically overt Cushing's syndrome, elevated UFC, and impaired cortisol suppression after the 1-mg DST. Among patients with elevated adrenal steroids, only patients with isolated cortisol excess were included (n ϭ 100), whereas patients with androgen excess alone or associated with cortisol excess were excluded (n ϭ 5).
For the 100 patients selected, tumor and tissue fragments obtained during surgery were immediately dissected by the pathologist. Tumor fragments were frozen and stored in liquid nitrogen until use and were available for nucleic acid extraction and CTNNB1 mutation analysis. Informed signed consent for genetic diagnosis, tumor analysis, and access to the data collected were obtained from all of the patients. The study was approved by our institutional review board (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale, Cochin Hospital, Paris).
Pathological examination and immunohistochemical analysis of ␤-catenin
Diagnosis of ACA was confirmed by a single experienced pathologist (F.T.) and Weiss score was established (20, 21) . To evaluate ␤-catenin content, sections, diagnosis, scoring, and immunohistochemistry were performed as previously described (3, 11, 22) . Briefly, sections, 4 mm thick, from formalin-fixed tissue embedded in paraffin were mounted on Superfrost/Plus glass slides. The paraffin was eliminated by incubating the sections in xylene and then rehydrating them. For antigen retrieval, sections were heated in a water bath for 40 min at 98 C in 10 mmol sodium citrate buffer at pH 6.0. The slides were incubated with CTNNB1 antibody (BD Bioscience, San Diego, CA; 1:400) for 60 min at room temperature. Sections were then incubated with the streptavidin-biotin-peroxidase complex, and the marker was detected by the enzymatic precipitation of 3.30-diaminobenzidine tetrahydrochloride in 0.5 mmol Tris. Finally, the slides were counterstained with Mayer's hematoxylin, and some sections were incubated without the primary antibody for negative controls. All ␤-catenin-stained sections were examined. Immunohistochemical labeling was evaluated for the presence of cytoplasmic and nuclear staining using qualitative (strong, moderate, weak), semiquantitative (percentage of cytoplasms stained), and quantitative methods [percentage of nuclei were counted with Leica Qwin V3 software (Leica Microsystem, Heerbrugg, Switzerland)]. Immunohistochemical analysis of ␤-catenin was conducted by two independent and blinded pathologists (F.T. and I.C.) unaware of clinicopathological-and ␤-catenin genetic analysis results. The following histological features were considered as abnormal ␤-catenin immunostaining: focal cytoplasmic staining for ␤-catenin (Ͻ30% of cytoplasms but strong cytoplasmic staining), diffuse cytoplasmic staining (30 -70% of cytoplasms and at least moderate cytoplasmic staining, Ͼ70% of cytoplasms whatever staining intensity) and/or focal nuclear staining (Ͻ5% of nuclei but strong nuclear staining), or diffuse nuclear staining (Ͼ5% of nuclei and at least moderate nuclear staining).
Nucleic acid extraction and mutation analysis of CTNNB1
Tumor DNA and RNA were extracted from tumors and purified by cesium chloride gradient ultracentrifugation as previously described (16, 23) . cDNA was synthesized by Moloney murine leukemia virus-reverse transcriptase (Invitrogen, Groningen, The Netherlands) using 1 g total RNA in a final reverse transcriptase mixture of 40 l. Mutation analysis of CTNNB1 was performed as previously described (3). Briefly, exon 3 and the flanking intronic sequences of CTNNB1 were amplified by PCR from tumor DNA. The primers used were hCATEX2F (GAAAATCCAGCGTGGACAATG) and hCATEX4R (TC-GAGTCATTGCATACTGTCC). Both strands of the amplified products were directly sequenced on an automated sequencer (ABI 3700; PerkinElmer, Boston, MA). To search for large CTNNB1 deletions, exon 3 was also amplified from tumor cDNA using the primers hCATF1 (GCGTGGACAATGGCTACT-CAAG) and hCATR2 (TTCAGCACTCTGCTTGTGGTCC). Mutations were confirmed twice in two independent experiments.
Statistical analysis
Quantitative variables were described using means and SDs. Qualitative variables were described using percentages. Due to the nonnormal distribution of several variables and to the small numbers of subjects in the groups of interest, nonparametric statistical methods were used to examine relationships between variables when appropriate (Fisher exact 2 test, Wilcoxon test). All reported P values are two sided. P Ͻ 0.05 were considered as statistically significant.
Results
Clinicopathological results
Of the 100 patients recruited for the study, 82 were women and 18 were men. The median age of the patient population was 48 (Ϯ13) years. Of the adrenal-gland resections, 60 were of the left adrenal gland and 40 were of the right adrenal glands. Forty-six patients had a CSA (elevated UFC) indicating clinically overt Cushing's syndrome. Adrenal adenoma was discovered incidentally in 54 patients. Of these, 19 patients had a SCSA (incomplete cortisol suppression with 1 mg DST and at least one additional biological abnormality of the HPA axis) without specific symptoms of Cushing's syndrome. The other 35 patients had a NSA with strictly normal HPA axis evaluation. Fifty-eight patients had Weiss scores equal to 0, 25 patients had a Weiss score equal to 1 (nuclear atypia ϭ 18, Ͻ25% of clear cells ϭ 7), and 17 patients had a Weiss score equal to 2 (nuclear atypia and Ͻ25% of clear cells) (Fig. 1) .
␤-catenin immunostaining analysis
Fifty-one of the ACA samples (51%) were positive for ␤-catenin on immunostaining (Fig. 1) indicating cytoplasmic and/or nuclear accumulation. Among these 51 samples, 41 (80%) presented with diffuse nuclear (Ͼ5% cells with at least moderate nuclear staining) and/or cytoplasmic (30 -70% of cytoplasms with at least moderate staining, or Ͼ70% of cytoplasms stained at any intensity) staining. On the other hand, focal cytoplasmic accumulation (Ͻ30% of cytoplasms but strong cytoplasmic staining) was present in only 20% of the tumors (n ϭ 10). About half of the cases (n ϭ 23, 45%) had nuclear accumulation of ␤-catenin.
Mutations in CTNNB1 were present in 70% of samples with nuclear and/or cytoplasmic accumulation of ␤-catenin. For samples with only cytoplasmic accumulation, 64% had CTNNB1 mutations, whereas for samples with only nuclear accumulation, 77% had CT-NNB1 mutations. Interestingly, no CTNNB1 mutation was found in case of tumors not harboring immunohistochemical accumulated ␤-catenin. Tumors with abnormally immunohistochemical accumulated ␤-catenin were mostly NSA (NSA, 47.1%; SCSA, 21.6%; CSA, 31.4%) whereas tumors without immunohistochemical accumulated ␤-catenin were mostly CSA (CSA, 61.2%; SCSA, 16.3%; NSA, 22.5%) (P Ͻ 0.01). Details of ␤-catenin immunostaining analysis are summarized in Fig. 2 .
␤-catenin genetic analysis
The results of the mutational analysis of CTNNB1 are summarized in Fig. 2 . Thirty-six of all ACA samples collected (36%) had genetic alterations in exon 3 of CTNNB1 (Fig. 1) . Most of the molecular alterations of CTNNB1 were heterozygous missense mutations of codon 45 in exon 3 of CTNNB1 (n ϭ 32). These missense mutations were responsible for an amino acid change from serine to proline (p.S45P) (n ϭ 19), serine to phenylalanine (p.S45F) (n ϭ 10), serine to tyrosine (p.S45Y) (n ϭ 1), serine to alanine (p.S45A) (n ϭ 1), proline to alanine and serine to proline (p.P44A_S45P) (n ϭ 1). Deletions (p.A5_A80del, p.S45del, p.G38del) or insertions (p.S33_G34insS), leading to alterations of exon 3, without frameshift, were found in the other four tumors (Fig. 2) . All of the 36 tumors with genetic alterations showed abnormally accumulated ␤-catenin. Of the other 64 tumors, only 15 (23.4%) presented with abnormally accumulated ␤-catenin (P Ͻ 0.0001) ( Table 1) . Tumors with molecular alterations of CTNNB1 were mostly NSA (NSA, 61.1%; SCSA, 22.2%; CSA, 16.7%), whereas wild-type tumors were mostly CSA (CSA, 62.5%; SCSA, 17.2%; NSA, 20.3%) (P Ͻ 0.0001). This suggested an association between CTNNB1 mutation and tumor cortisol secretion (Table 1) . In ACA samples with CTNNB1 mutations, tumor size and tumor weight were significantly higher [re- (Fig. 1) . Interestingly, in NSA with CTNNB1 mutations, tumor size and tumor weight were also significantly higher [respectively, 4.4 cm (Ϯ1.4) and 30.7 g (Ϯ25.
3)] than in NSA without molecular alterations of CTNNB1 [3.6 cm (Ϯ0.6) and 20.3 g (Ϯ5.9) (P Ͻ 0.05)].
Discussion
Activation of the Wnt/␤-catenin signaling pathway plays an important role in tumorigenesis and has been identified in numerous tumors, including colorectal, hepatocellular, and endometrial cancers (4 -10). Activation of the Wnt/␤-catenin signaling pathway, determined by immunohistochemical staining of cytoplasmic and nuclear ␤-catenin, has recently been demonstrated in ACCs (3, 24, 25) as well as in benign ACT such as ACA or primary pigmented nodular adrenocortical disease (PPNAD) (3, 11, 13, 14) . However, the frequency of cases in which this occurs is unclear because of the small numbers of samples studied. In normal human adrenal, the Wnt/␤-catenin signaling pathway has not been extensively studied and in two reports including normal adrenal, no ␤-catenin accumulation was found but only a membranous signal (13, 14) , whereas in adrenals' mice an accumulation has been found but only in the glomerulosa (15) . In the present study of 100 resected ACA samples, we used ␤-catenin immunohistochemistry and somatic CTNNB1 mutation analysis to assess the frequency of Wnt/␤-catenin pathway activation and to determine its phenotypic effects.
In our series, abnormal cytoplasmic and/or nuclear ␤-catenin immunohistochemical staining was seen in 51% of the ACA, supporting an activation of the Wnt/␤-catenin signaling pathway. In a previous series, we have reported cytoplasmic and/or nuclear staining in 10 of the 26 studied ACA samples (38%), with mostly only focal cytoplasmic staining (3). In the series of Tadjine et al. (13) , all of the five studied ACA samples (excluding Conn's adenoma) showed an abnormal accumulation of ␤-catenin. The three ACA with CTNNB1 mutations showed nuclear and cytoplasmic staining, whereas for the two nonmutated tumors, ␤-catenin was only accumulated in the cytoplasm (13) . These findings suggest that immunohistochemical nuclear staining is a frequent event in mutated ACA, and in our series 50% of the mutated cases showed nuclear staining. Nevertheless, in 50% of the ACA samples harboring a somatic ␤-catenin mutation, only cytoplasmic accumulation was detected, suggesting decreased ␤-catenin degradation. We found the similar frequencies of CTNNB1 mutations in the group of tumors with ␤-catenin nuclear staining (78%) and in the group of tumors with only cytoplasmic ␤-catenin staining (64%) (P ϭ 0.4). No phenotypical difference was observed between the two groups of tumors suggesting that the CTNNB1 mutation is a determinant factor in the ␤-catenin staining. Moreover, cytoplasmic staining also seems to be a good tool to identify ACA with activated Wnt/␤-catenin signaling pathway. This does not exclude the involvement of other factors that modulate ␤-catenin translocation in the nucleus, which could participate to adrenocortical tumorigenesis. Nevertheless, an adrenal-specific target of the Wnt/␤-catenin signaling pathway would be a very useful tool to assess the specific biologic effect of either cytoplasmic or nuclear ␤-catenin accumulation on immunohistochemistry. In the liver the GLUL gene encodes glutamine synthetase, which appears to be the most reliable marker of Wnt/ ␤-catenin signaling pathway activation (26).
On immunohistochemistry, the Wnt/␤-catenin signaling pathway was activated in more than half of the ACA cases, although on genetic analyses, it indicated the presence of CTNNB1 mutations in only 36% of the tumors. Even if this discrepancy is consistent with several previous observations (3, 11, 13) , it is possible that this difference may be due to an overstatement of the cytoplasmic staining, especially as regards diffuse cytoplasmic staining. However, it also suggests that other mechanisms may be involved in the activation of Wnt/␤-catenin signaling. Several hypotheses have been proposed to explain ␤-catenin accumulation in tumors without CTNNB1 mutation, such as cross talk between the Wnt/␤-catenin signaling pathways and the IGF system in ACCs (3, 27) or the cAMP signaling pathway in PPNAD (3, 11, 13) . Other genetic defects could also be involved, such as those in the APC gene, which have been reported in ACC samples (28, 29) .
We showed that a missense mutation of Ser 45 in exon 3 was the most frequent genetic alteration of CTNNB1, representing about 90% of CTNNB1 alterations in ACA in our series. Functional studies using a human ACC cell line (H295R), harboring a spontaneously occurring activating Ser 45 ␤-catenin mutation, showed a constitutive activation of T cell factordependent transcription (3). This demonstrates that the activating mutation of the Ser 45 in CTNNB1 has nuclear effects on gene expression regulation in adrenocortical cells (3) . Accordingly, these mutations lead to Wnt/␤-catenin signaling pathway activation with potential biological effects on cell growth and differentiation. Our study includes the first large series that has demonstrated the Ser 45 point mutation with such a high frequency compared with the other CTNNB1 mutations. Indeed, among CTNNB1 mutations, point mutation of Ser 45 was identified in less than 50% of cases of hepatocellular carcinomas (26, 30) and in less than 60% of cases in colon cancer (31) (32) (33) .
In our series, we observed clear genotype/phenotype correlation when mutated ACAs were larger and mostly nonsecreting. Although these findings may be biased by the fact that NSAs were mainly operated on the basis of tumor size, this potential bias cannot alone explain the phenotype of mutated ACA insofar as size and weight of NSA with CTNNB1 mutations were significantly higher than NSA without mutation of CTNNB1. This was of interest because a clear genotype/phenotype correlation is not always so evident in benign tumors. A series of thyroid follicular adenomas with ␤-catenin accumulation in immunohistochemistry were not associated with any particular phenotype, although aberrant activation of Wnt/␤-catenin signaling seems to be strongly involved in papillary thyroid cancer (34) . For hepatocellular adenomas, the identification of strong genotype-phenotype correlations had suggested that adenomas with Wnt/␤-catenin signaling pathway activation had a higher risk of malignant transformation (17, 18) ; in addition to their well-differentiated pattern, these tumors had other significant features such as a homogeneous microtrabeculoacinar pattern, low-grade cellular atypia, and cholestasis (26) . The phenotype/genotype correlation observed in our series, in which mutated tumors were larger and mostly nonsecreting, is consistent with previous observations in which CTNNB1 mutations were restricted to a rare phenotype of PPNAD with larger nodules than usual (11) . One possible explanation for this association is that Wnt/␤-catenin signaling could either increase cell proliferation via controlling cell cycle genes as MYC (35) or decrease apoptosis via genes such as BIRC5 (survivin) (36) .
Concerning the hormonal consequences of Wnt/␤-catenin pathway activation, our results demonstrate (as suggested in an our initial our study in 26 ACAs) that tumors with CTNNB1 mutations were predominantly NSAs (67%) (3). These results are also supported by those of Masi et al. (37) on six ACAs with somatic CTNNB1 activating mutations, who reported that mutated tumors were predominantly NSAs (66.7%) but are inconsistent with the findings of Tadjine et al. (13) , who reported that tumors with CTNNB1 mutations were predominantly CSAs (75%). However, regarding results of Masi et al. and Tadjine et al., only six and four ACA with CTNNB1 mutation were respectively studied, which limit the significance of these observations. These findings, however, are valid for unilateral adenomas and do not apply to all types of tumors. They must take account of genetic background and germline genetic abnormalities because it has been shown in one PPNAD (leading to Cushing syndrome) with germline PRKRA1A mutations, a single large nodule with somatic CTNNB1 mutation (14) . There is also evidence for the involvement of the Wnt/␤-catenin signaling pathway in adrenocortical steroid regulation. In transgenic mice with constitutive activation of ␤-catenin in the adrenal cortex, an effect on aldosterone production has been reported (15) . Furthermore, reducing ␤-catenin-dependent transcription in a H295R cell line (representing constitutive activation of the Wnt/␤-catenin signaling pathway) with a CK2 inhibitor (38) decreases the secretion of aldosterone, dehydroepiandrosterone sulfate, and androstendione and results in an accumulation of 17-hydroxyprogesterone (39) . Nevertheless, more studies are required to better understand the consequences of Wnt/ ␤-catenin signaling on steroid secretion, including glucocorticoid and aldosterone, in the adrenal gland.
Conclusion
Wnt/␤-catenin pathway activation as shown by nuclear and/or cytoplasmic ␤-catenin accumulation is frequent, 
